PIPELINE

Pre-clinical

Phase I

Phase II

Phase III

NDA


CUTX-101 (Copper Histidinate) for Menkes Disease

NDA in preparation
80%

AAV-ATP7A Gene Therapy for Menkes Disease

Preclinical
17%


= Orphan Drug Designation
= Fast Track Designation
= Rare Pediatric Disease
= Orphan Medicinal Product (Positive Opinion Granted)
= Breakthrough Therapy Designation